Background: Sexually transmitted infections (STIs), including chlamydia, gonorrhea, and syphilis are a significant public health concern in the United States, particularly among young adult sexual and gender minority (SGM) populations who use substances. While prior research links specific substances to HIV and STI risk in men who have sex with men (MSM), less has been studied on how different types of substance use relate to STI outcomes in gender-diverse young adults who use substances in the context of sexual behavior.
Methods: Cross-sectional data was analyzed from 420 SGM young adults who reported using substances in the context of sexual behavior in the past 3 months were recruited nationally to examine associations between recent substance use (prior 6 months) and STI outcomes. Participants completed a quantitative survey on sociodemographics, PrEP status, and substance use, and a subset (n=233, 55.5%) submitted laboratory-confirmed STI test results through at-home kits or provider documentation. Firth Multivariable logistic regression models were used to assess associations between self-reported and laboratory-confirmed STIs and recent use of substances, adjusting for age, gender, race/ethnicity, educational attainment, and HIV pre-exposure prophylaxis (PrEP) use.
Results: Poppers use was consistently associated with increased odds of STI positivity across both self-report and lab-confirmed outcomes. In self-report data, poppers use was associated with gonorrhea (aOR = 3.89, 95% CI: 1.64–11.04) and any STI (aOR = 2.93, 95% CI: 1.55–5.96). Polydrug use was linked to syphilis (aOR = 8.52, 95% CI: 1.01–1112.53) and any STI (aOR = 1.85, 95% CI: 1.07–3.30). In lab-confirmed results, poppers use remained significantly associated with any STI (aOR = 3.98, 95% CI: 1.42–15.08) and syphilis via kit testing (aOR = 4.55, 95% CI: 1.11–41.35). Stimulant use was also associated with syphilis (aOR = 3.07, 95% CI: 1.12–9.55), and opioid use showed strong associations with syphilis (aOR = 25.67, 95% CI: 2.83–381.96) and any STI (aOR = 15.92, 95% CI: 1.66–249.23), though estimates were imprecise. Cannabis use was associated with lower odds of gonorrhea (aOR = 0.18, 95% CI: 0.04–0.76).
Conclusion: Use of poppers, stimulants, opioids, as well as use of three or more drugs concurrently and prescription drug misuse was associated with increased odds of both self-reported and laboratory-confirmed STIs among SGM young adults. Findings suggest substance use is a behavioral marker of heightened sexual health risk. Interpretation should be cautious given the study’s cross-sectional design, missing data, and potential biases. Longitudinal research is needed to clarify pathways and inform targeted interventions.